Annals of Surgical Oncology

, Volume 22, Issue 6, pp 1996–2002 | Cite as

Hospitalization for Inflammatory Bowel Disease is Associated with Increased Risk of Breast Cancer: A Nationwide Cohort Study of an Asian Population

  • Ming-Shian Tsai
  • Hsin-Pao Chen
  • Chao-Ming Hung
  • Po-Huang Lee
  • Cheng-Li Lin
  • Chia-Hung Kao
Breast Oncology



To learn whether women with inflammatory bowel disease (IBD) exhibit a higher risk of breast cancer.


We identified 4,856 women with IBD symptoms from 1998 to 2008 and 19,424 control patients without the disorder, frequency matched by age, sex, and admission year. Both cohorts were followed-up until the end of 2010 to estimate the risk of breast cancer.


Overall, the incidence of breast cancer was similar in the IBD and control cohorts (1.31 vs. 1.25 per 1,000 person-years). The adjusted hazard ratio of breast cancer was 0.95 (95 % confidence interval 0.66–1.36) for the IBD patients. Further analysis revealed that neither Crohn disease nor ulcerative colitis was associated with the risk of developing breast cancer in women. The age-specific analysis indicated that the incidence of breast cancer was highest in the 45- to 65-year-old age group in both cohorts. The incidence of breast cancer was significantly increased in patients who required hospitalization twice or more per year, compared with the control cohort (adjusted hazard ratio 8.45; 95 % confidence interval 4.64–15.4). Moreover, age-specific analysis showed that patients aged less than 65 years old (≤44 or 45–65 years of age) exhibited a strong association between IBD hospitalization and breast cancer risk.


The risk of breast cancer was positively proportional to the frequency of admission for IBD. Therefore, careful surveillance of breast cancer should be sought for female IBD patients with 2 or more annual hospitalizations.


Breast Cancer Inflammatory Bowel Disease Breast Cancer Risk Inflammatory Bowel Disease Patient Crohn Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was partially supported by study projects of China Medical University (CMU102-BC-2); Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW103-TDU-B-212-113002), Health and welfare surcharge of tobacco products, China Medical University Hospital Cancer Research Center of Excellence (MOHW103-TD-B-111-03, Taiwan); and the International Research-Intensive Centers of Excellence in Taiwan (NSC101-2911-I-002-303). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


The authors declare no conflict of interest.

Supplementary material

10434_2014_4198_MOESM1_ESM.docx (16 kb)
Supplementary material 1 (DOCX 15 kb)


  1. 1.
    DeSantis C, et al. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:408–18.CrossRefGoogle Scholar
  2. 2.
    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45.CrossRefPubMedGoogle Scholar
  3. 3.
    Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Harris RE, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res. 2003;63:6096–101.PubMedGoogle Scholar
  5. 5.
    Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep. 1999;6:71–4.PubMedGoogle Scholar
  6. 6.
    Knupfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat. 2007;102:129–35.CrossRefPubMedGoogle Scholar
  7. 7.
    Pierce BL, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27:3437–44.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Pierce BL, et al. Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Cancer Res Treat. 2009;114:155–67.CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Bernstein CN, et al. Cancer risk in patients with inflammatory bowel disease. Cancer. 2001;91:854–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Jess T, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology. 2006;130:1039–46.CrossRefGoogle Scholar
  11. 11.
    Askling J, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005;54:617–22.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol. 2008;14:378.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Jess T, et al. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol. 2013;108:1869–76.CrossRefPubMedGoogle Scholar
  14. 14.
    Thia KT, et al. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103:3167–82.CrossRefPubMedGoogle Scholar
  15. 15.
    Bernstein CN. Assessing environmental risk factors affecting the inflammatory bowel diseases: a joint workshop of the Crohn’s & Colitis Foundations of Canada and the USA. Inflamm Bowel Dis. 2008;14:1139–46.CrossRefPubMedGoogle Scholar
  16. 16.
    Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut. 2008;57:1185–91.CrossRefPubMedGoogle Scholar
  17. 17.
    Gasche C, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1545–53.CrossRefPubMedGoogle Scholar
  18. 18.
    Sun LM, et al. Increased breast cancer risk for patients with multiple sclerosis: a nationwide population-based cohort study. Eur J Neurol. 2014;21:238–44.CrossRefPubMedGoogle Scholar
  19. 19.
    Chung WS, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 2014;73(10):1774–80.Google Scholar
  20. 20.
    Tsai MS, et al. Long-term risk of acute coronary syndrome in patients with inflammatory bowel disease: a 13-year nationwide cohort study in an Asian population. Inflamm Bowel Dis. 2014;20:502–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Shen YC, et al. Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: implications from age-period-cohort analysis. Cancer Epidemi Biomarkers Prev. 2005;14:1986–90.CrossRefGoogle Scholar
  22. 22.
    Lin T, Chen K, MacMahon B. Epidemiologic characteristics of cancer of the breast in Taiwan. Cancer. 1971;27:1497–504.CrossRefPubMedGoogle Scholar
  23. 23.
    Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA. 2014;311:1327–35.CrossRefPubMedGoogle Scholar
  24. 24.
    Federico A, et al. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer. 2007;121:2381–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Kruidenier LA, Verspaget H. Oxidative stress as a pathogenic factor in inflammatory bowel disease—radicals or ridiculous? Aliment Pharmacol Ther. 2002;16:1997–2015.CrossRefPubMedGoogle Scholar
  26. 26.
    D’Odorico A, Bortolan S, Cardin R, et al. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand J Gastroenterol. 2001;36:1289–94.CrossRefGoogle Scholar
  27. 27.
    Zhu H, Li YR. Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence. Exp Biol Med. 2012;237:474–80.CrossRefGoogle Scholar
  28. 28.
    Tas F, et al. Oxidative stress in breast cancer. Med Oncol. 2005;22:11–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Ambrosone CB, et al. Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res. 1999;59:602–6.PubMedGoogle Scholar
  30. 30.
    Kruidenier L, et al. Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease. J Pathol. 2003;201:7–16.CrossRefPubMedGoogle Scholar
  31. 31.
    Drossman DA, et al. Health-related quality of life in inflammatory bowel disease. Dig Dis Sci. 1989;34:1379–86.CrossRefPubMedGoogle Scholar
  32. 32.
    Stewart T, et al. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet. 1995;346(8978):796–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Frisch M, et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285:1736–45.CrossRefPubMedGoogle Scholar
  34. 34.
    Kasiske BL, et al. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4:905–13.CrossRefPubMedGoogle Scholar
  35. 35.
    Adler A, Stein JA, Ben-Efraim S. Efraim, Immunocompetence, immunosuppression, and human breast cancer. III. Prognostic significance of initial level of immunocompetence in early and advanced disease. Cancer. 1980;45:2074–83.CrossRefPubMedGoogle Scholar
  36. 36.
    Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation. 1993;55:742–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Rosato V, et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol. 2011;22:2687–92.CrossRefPubMedGoogle Scholar
  38. 38.
    Esposito K, et al. Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause. 2013;20:1301–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Esposito K, et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35:2402–11.CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Healy LA, et al. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol). 2010;22:281–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Kuhl H. Breast cancer risk in the WHI study: the problem of obesity. Maturitas. 2005;51:83–97.CrossRefPubMedGoogle Scholar
  42. 42.
    Levy E, et al. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr. 2000;71:807–15.PubMedGoogle Scholar
  43. 43.
    Ananthakrishnan AN, et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn’s disease. Gut. 2014;63:776–84.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Chajès V, et al. Association between serum trans-monounsaturated fatty acids and breast cancer risk in the E3N-EPIC study. Am J Epidemiol. 2008;167:1312–20.CrossRefPubMedCentralPubMedGoogle Scholar
  45. 45.
    Lai MS, et al. Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases: Taiwan multicentre cancer screening (TAMCAS). Int J Cancer. 1998;78:21–6.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Ming-Shian Tsai
    • 1
  • Hsin-Pao Chen
    • 2
  • Chao-Ming Hung
    • 1
  • Po-Huang Lee
    • 1
  • Cheng-Li Lin
    • 3
    • 4
  • Chia-Hung Kao
    • 5
    • 6
  1. 1.Department of General SurgeryE-Da Hospital and I-Shou UniversityKaohsiungTaiwan
  2. 2.Department of Colorectal SurgeryE-Da Hospital and I-Shou UniversityKaohsiungTaiwan
  3. 3.Management Office for Health DataChina Medical University HospitalTaichungTaiwan
  4. 4.College of MedicineChina Medical UniversityTaichungTaiwan
  5. 5.Graduate Institute of Clinical Medical Science and School of Medical, College of MedicineChina Medical UniversityTaichungTaiwan
  6. 6.Department of Nuclear Medicine and PET CenterChina Medical University HospitalTaichungTaiwan

Personalised recommendations